Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Shares Bought by Epoch Investment Partners Inc.

Epoch Investment Partners Inc. increased its position in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) by 195.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 535,999 shares of the company’s stock after buying an additional 354,728 shares during the period. Epoch Investment Partners Inc. owned 1.32% of Pacira Pharmaceuticals worth $20,127,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Stonepine Capital Management LLC bought a new position in Pacira Pharmaceuticals in the 3rd quarter valued at about $14,089,000. Stifel Financial Corp bought a new position in shares of Pacira Pharmaceuticals during the 3rd quarter worth approximately $353,000. OxFORD Asset Management LLP lifted its position in shares of Pacira Pharmaceuticals by 6.4% during the 3rd quarter. OxFORD Asset Management LLP now owns 65,241 shares of the company’s stock worth $2,525,000 after buying an additional 3,933 shares in the last quarter. Elk Creek Partners LLC lifted its position in shares of Pacira Pharmaceuticals by 10.7% during the 3rd quarter. Elk Creek Partners LLC now owns 612,049 shares of the company’s stock worth $22,982,000 after buying an additional 59,393 shares in the last quarter. Finally, Westfield Capital Management Co. LP lifted its position in shares of Pacira Pharmaceuticals by 5.3% during the 3rd quarter. Westfield Capital Management Co. LP now owns 1,285,850 shares of the company’s stock worth $48,284,000 after buying an additional 64,510 shares in the last quarter.

A number of equities research analysts recently commented on PCRX shares. Zacks Investment Research cut shares of Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, October 9th. Canaccord Genuity reaffirmed a “buy” rating and issued a $44.00 price target (down previously from $48.00) on shares of Pacira Pharmaceuticals in a report on Sunday, October 1st. CIBC started coverage on shares of Pacira Pharmaceuticals in a report on Thursday, September 7th. They issued a “market perform” rating on the stock. Wedbush reaffirmed an “outperform” rating and issued a $87.00 price target on shares of Pacira Pharmaceuticals in a report on Wednesday, October 25th. Finally, Needham & Company LLC reiterated a “buy” rating on shares of Pacira Pharmaceuticals in a research note on Tuesday, September 26th. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eight have given a buy rating to the stock. Pacira Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $48.86.

Pacira Pharmaceuticals, Inc. (PCRX) opened at $43.85 on Friday. The company has a debt-to-equity ratio of 1.03, a current ratio of 6.99 and a quick ratio of 6.24. Pacira Pharmaceuticals, Inc. has a 1 year low of $29.81 and a 1 year high of $58.95.

Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its quarterly earnings results on Wednesday, November 8th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.15. The business had revenue of $67.30 million during the quarter, compared to the consensus estimate of $68.99 million. Pacira Pharmaceuticals had a negative net margin of 18.25% and a negative return on equity of 13.77%. The firm’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.20 earnings per share. analysts forecast that Pacira Pharmaceuticals, Inc. will post -0.85 EPS for the current fiscal year.

In related news, Director Mark A. Kronenfeld purchased 1,000 shares of the firm’s stock in a transaction that occurred on Friday, November 10th. The stock was bought at an average cost of $41.60 per share, with a total value of $41,600.00. Following the completion of the purchase, the director now directly owns 6,795 shares in the company, valued at $282,672. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Kristen Marie Williams sold 10,000 shares of the company’s stock in a transaction dated Friday, November 17th. The stock was sold at an average price of $40.00, for a total transaction of $400,000.00. Following the completion of the sale, the chief accounting officer now owns 23,455 shares in the company, valued at approximately $938,200. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 69,735 shares of company stock valued at $2,692,594. Insiders own 6.60% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This news story was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://ledgergazette.com/2017/12/16/pacira-pharmaceuticals-inc-pcrx-stake-raised-by-epoch-investment-partners-inc.html.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Institutional Ownership by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply